KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Debt (2018 - 2026)

Castle Biosciences' Total Debt history spans 6 years, with the latest figure at $10.1 million for Q4 2025.

  • On a quarterly basis, Total Debt changed 0.34% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 0.34% change, with the full-year FY2025 number at $10.1 million, changed 0.34% from a year prior.
  • Total Debt hit $10.1 million in Q4 2025 for Castle Biosciences, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Total Debt for CSTL hit a ceiling of $20.8 million in Q1 2022 and a floor of $10.0 million in Q1 2024.
  • Historically, Total Debt has averaged $11.2 million across 3 years, with a median of $10.0 million in 2025.
  • The widest YoY moves for Total Debt: up 0.34% in 2025, down 0.32% in 2025.
  • Tracing CSTL's Total Debt over 3 years: stood at $20.8 million in 2022, then plummeted by 51.93% to $10.0 million in 2024, then increased by 0.34% to $10.1 million in 2025.
  • Business Quant data shows Total Debt for CSTL at $10.1 million in Q4 2025, $10.0 million in Q3 2025, and $10.0 million in Q2 2025.